| ALCAR Stock | | | EUR 1.09 0.01 0.91% |
Executive
Ms. Pascale dArbonneau was appointed as Chief Financial and Administrative Officer of CARMAT SA as of December 12, 2018. She is a member of the National Association of Financial and Management Control and a lecturer at the University Paris Diderot. She is graduate of ESCP. Before joining CARMAT, Ms. dArbonneau was Executive Director at the Econocom International B.V. family office. She began her career in 1989 as an auditor at Coopers Lybrand before joining the pharmaceutical industry as Finance IT Director France at Johnson Johnson MSD . She spent most of her career at GlaxoSmithKline . She started as Director of Management Control France at GlaxoWellcome, before the merger with SmithKline Beecham, where she led a team of 20 people working on the merger of the two companies. She then held several senior positions within the Group before becoming Vice President Finance in charge of the integration of Compliance and Control at worldwide level. since 2018.
| Tenure | 6 years |
| Phone | 33 1 39 45 64 50 |
| Web | https://www.carmatsa.com |
Carmat Management Efficiency
The company has return on total asset
(ROA) of
(0.3856) % which means that it has lost $0.3856 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(2.5378) %, meaning that it generated substantial loss on money invested by shareholders. Carmat's management efficiency ratios could be used to measure how well Carmat manages its routine affairs as well as how well it operates its assets and liabilities.
Carmat has accumulated 52.02
M in total debt with debt to equity ratio
(D/E) of 22.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Carmat has a current ratio of 2.66, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Carmat until it has trouble settling it off, either with new capital or with free cash flow. So, Carmat's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Carmat sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Carmat to invest in growth at high rates of return. When we think about Carmat's use of debt, we should always consider it together with cash and equity.
Similar Executives
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. The company was founded in 2008 and is based in Vlizy-Villacoublay, France. CARMAT operates under Medical Instruments Supplies classification in France and is traded on Paris Stock Exchange. It employs 81 people. Carmat (ALCAR) is traded on Euronext Paris in France and employs 171 people.
Management Performance
Carmat Leadership Team
Elected by the shareholders, the Carmat's board of directors comprises two types of representatives: Carmat inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carmat. The board's role is to monitor Carmat's management team and ensure that shareholders' interests are well served. Carmat's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carmat's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carmat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Carmat a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Carmat Stock Analysis
When running Carmat's price analysis, check to
measure Carmat's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmat is operating at the current time. Most of Carmat's value examination focuses on studying past and present price action to
predict the probability of Carmat's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmat's price. Additionally, you may evaluate how the addition of Carmat to your portfolios can decrease your overall portfolio volatility.